In this QCast episode, co-hosts Jullia and Tom explore phase 2b in clinical trials and why it carries so much weight in the path towards phase 3. They clarify what phase 2b means in day-to-day development work: a more focused stage of clinical testing where teams aim to reduce uncertainty around dose, target population, endpoint strategy, and the likely treatment effect before committing to a larger and more expensive confirmatory programme. The conversation focuses on where programmes are most exposed at this stage, including overly broad design, weak endpoint fit, operational noise around visits and dosing, and the knock-on effect those issues can have on how confidently results can be interpreted.
They also discuss what phase 2b is really there to do. It is not simply a larger repeat of earlier exploratory work, and it is not a substitute for phase 3 confirmation. Instead, it sits in the space where sponsors need evidence that is disciplined enough to support the next major decision. Along the way, Jullia and Tom highlight common misconceptions and failure modes, such as treating phase 2b as a fixed template, carrying too much complexity into the protocol, or relying on data that looks promising but does not translate cleanly into later study planning.
🎧 Listen to the Episode:
Key Takeaways
What Phase 2b Is and Why It Matters
Phase 2b is typically the point where a clinical programme shifts from broad exploration to a more deliberate decision-making stage. By then, a treatment has usually shown an acceptable early safety profile and some indication of activity, and the focus turns to whether the selected regimen, endpoint approach, and patient population are strong enough to justify phase 3. The value of phase 2b lies in its ability to reduce uncertainty before the next investment decision. When designed well, it gives teams a clearer estimate of treatment effect and a more credible basis for later development planning.
How Phase 2b Risk Shows Up in Practice
Risk at this stage often appears through execution details that interfere with interpretation. Visit timing, dosing control, rescue medication rules, endpoint consistency, and missing key assessments can all affect whether the study produces a clean answer. Recruitment can also become more difficult if the population is closer to the eventual phase 3 target, and retention problems can weaken the reliability of a key readout. Teams also create avoidable ambiguity when they include too many treatment arms, chase too many secondary objectives, or use endpoints that are interesting scientifically but do not support a clear development decision.
Design, Analysis, and Best Practice for the Next Step
A strong phase 2b study is usually built around a focused comparison that can support a real next move in the programme. Randomisation, blinding, and a well-chosen endpoint all help strengthen interpretability, while the observed effect size and variability often feed directly into phase 3 planning. This stage also gives teams a chance to test operational assumptions they may carry forward later, from assessment schedules to data review cadence. Good practice includes keeping the design tightly aligned to the core decision, protecting the small number of assessments that drive interpretation, and being realistic about missing data, variability, and recruitment when planning the analysis.
Full Transcript
Jullia
Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.
Tom
I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.
Jullia
Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.
Tom
Today we’re talking about phase 2b in clinical trials. Now when a team says a programme is heading into phase 2b, what are they usually trying to achieve?
Jullia
So they’d be trying to reduce uncertainty before a very expensive next step. By that point, the treatment has usually shown an acceptable safety profile and some early signal of activity. So now the question becomes whether that signal is solid enough, at the right dose, in the right population, to justify phase 3.
And that’s why phase 2b matters so much. It’s where a programme starts to move from learning broadly to making a sharper development decision. Teams need real data they can actually act on.
Tom
So it’s basically a decision stage, but with a lot riding on the quality of that decision.
Jullia
Exactly. And you can hear that in how these studies are designed. Earlier work may still be exploring a wider dose range or trying to understand where the treatment effect might sit. By phase 2b, you’re usually carrying forward a smaller number of viable regimens and asking more focused questions.
The simplest way to think about it is this. A phase 2b study is there to tell you whether your chosen treatment approach holds up when you test it more deliberately. That includes the dose, the endpoints, the patient population, and the analysis framework you’ll need later.
Tom
I think that’s the bit people underestimate. The label sounds like a small step inside phase 2, but the consequences are pretty big.
Jullia
They are. And although teams often talk about phase 2a and phase 2b, those are working distinctions inside the broader development path. What matters most is the objective of the study. Early phase 2 work often looks for signal and helps refine assumptions. Phase 2b is more disciplined. You’re trying to get to a credible estimate of treatment effect and enough confidence to plan what comes next.
You also tend to see a study population that looks more like the one you expect in later development. Inclusion criteria is clearer and comparisons are tighter. The protocol usually leaves less room for interpretation, because ambiguity at this stage becomes expensive very quickly.
Tom
Now I suppose that’s where people start calling it almost a mini confirmatory study, even though it’s not phase 3?
Jullia
Yes, and that phrase can be useful if you don’t push it too far. It captures the fact that phase 2b has more rigour than earlier exploratory work. But it still isn’t doing the job of a full confirmatory trial. You’re not usually aiming for submission-grade confirmation here. You’re trying to decide whether the effect is robust enough to earn that larger investment.
A common scenario is a programme that saw a promising efficacy signal in an earlier cohort, but the dose range was broad and the endpoint strategy still needs tightening. Phase 2b is where the team narrows that down. They may test one or two selected doses against control, use a more settled endpoint, and look for a result that can support phase 3 assumptions with less guesswork.
Tom
Now could you provide an example of where that shows up in delivery?
Jullia
So think about visit scheduling and endpoint collection. In an earlier exploratory study, you might tolerate a slightly looser visit window if you’re mainly looking for directional signal. However, in phase 2b, visit timing often matters more because you’re trying to estimate the treatment effect cleanly at prespecified timepoints.
Or take dose changes for example. If a regimen is meant to represent the candidate dose for later development, you need tight control over dosing records, deviations, and rescue medication rules. Once those start drifting, interpretation gets harder. The same goes for lab uploads, query turnaround, and endpoint adjudication. Small operational issues can start to affect the core question the study is supposed to answer.
Tom
I feel like that leads neatly into design. Now what does a solid phase 2b design usually look like?
Jullia
Well most of the time you’ll see randomised controlled comparisons, because teams want a clearer read on efficacy and a cleaner basis for inference. Blinding is often important as well, especially when endpoints involve some degree of clinical judgement or patient reporting. The study still needs to be efficient, but internal validity matters a lot at this point.
Endpoint choice is also more consequential. You want something that reflects a meaningful treatment effect and gives continuity into later development. That might be a clinical outcome, a validated biomarker, or a composite endpoint, depending on the disease area and mechanism. The key is that the endpoint should support a real decision. If it gives you a signal that can’t translate into phase 3 planning, it hasn’t done enough work.
There’s also a continuity piece that people don’t always talk about. Phase 2b often pilots the operational model you may carry forward later. Assessment schedules, data review cadence, central monitoring expectations, and analysis conventions can all get stress-tested here.
Tom
So phase 2b isn’t only about whether the drug seems to work. It’s also where the whole future study model gets a rehearsal.
Jullia
More or less. It's not necessarily a full dress rehearsal, but enough to expose weak assumptions. You might learn that your eligibility criteria create too much heterogeneity. Or that the endpoint is clinically interesting but difficult to collect consistently across sites. Or that your stratification factors need refinement because baseline imbalance could create noise you don’t want later.
And there’s a statistical consequence to all of this. The effect size and variability you observe in phase 2b often feed directly into phase 3 sample size planning. If those estimates are unstable, overly optimistic, or based on avoidable operational noise, the next study can be underpowered or badly calibrated from day one.
Tom
What tends to go wrong there?
Jullia
Well a few things come up repeatedly. Recruitment can be slower than teams expect, because the study population is often closer to the later-stage target population and that can narrow the funnel. Retention can also become a problem if visit burden is high or follow-up is long.
Then there’s endpoint fit. Sometimes a study collects something that looks scientifically interesting but doesn’t support a clean development decision. You end up with data, but not clarity. Another risk is unnecessary complexity. Too many treatment arms, too many secondary objectives, too much flexibility in analysis, and suddenly the study is carrying more ambiguity than it should.
Missing data is another one. If you’ve built your decision around a key timepoint and a meaningful chunk of patients miss that assessment, the interpretation gets messy fast. Even routine things like delayed adverse event coding or unresolved data queries can slow database readiness and complicate the readout.
Tom
That’s a useful summary, actually. Phase 2b can fail because the biology is weak, but it can also fail because the study didn’t produce a clean answer.
Jullia
Yes, and that distinction matters. A negative result can still be informative if the design and execution were strong. An inconclusive result is harder to use. It leaves sponsors deciding whether to spend more money clarifying something that might have been answered the first time.
There’s also a misconception that phase 2b has a typical fixed shape or timeline. It doesn’t. Duration depends on the indication, the endpoint, follow-up needs, and how easy the target population is to recruit. Some studies run for months, others much longer. Teams shouldn’t anchor on a generic timeline. They should anchor on what evidence is needed for the next decision.
A short aside here, because this comes up in meetings more often than you’d think. People sometimes ask about phase 2c. You do hear the term occasionally, but it isn’t a standard label with a consistent meaning. Most teams are better served by describing the study’s purpose clearly instead of inventing another sub-phase.
Tom
I’m glad you mentioned that, because it does crop up. Usually when a programme sits in that awkward space between dose confirmation and full phase 3 planning.
Jullia
Exactly, and clearer language usually solves the problem. Say whether the study is still dose-refining, whether it’s supporting endpoint selection, or whether it’s effectively phase 3 enabling. That tells people more than an extra label ever will.
And before we wrap up, there are a few practical takeaways I’d like to address. Keep the design focused around a decision the study genuinely needs to answer. Choose endpoints that can support later development, not just early excitement. Protect data quality around the handful of assessments that drive interpretation. And be realistic about variability, recruitment, and missing data when you plan the analysis.
Tom
That’s probably the best lens for time-poor teams. Ask whether the study will give you a reliable next move. If the answer is shaky, the protocol probably needs more work.
Jullia
Yes, and that’s really the heart of it. Phase 2b should help a team move forward with discipline. You want a clear view of efficacy and safety at a viable regimen, a sensible basis for phase 3 assumptions, and enough operational learning to avoid repeating preventable mistakes at larger scale.
So if we boil it down, three things stand out. Phase 2b is where development decisions become more evidence-led, design choices start carrying much more weight, and execution quality has a direct effect on how trustworthy the result is. When those pieces line up, the next phase is built on something solid.
And when they don’t, the programme can spend a lot of time and money chasing uncertainty that should have been reduced earlier.
Jullia
With that, we’ve come to the end of today’s episode on phase 2b in clinical trials. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.
Tom
Thanks for tuning in, and we’ll see you in the next episode.
About QCast
QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.
Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.
